OCA
NUVB icon

Octagon Capital Advisors’s Nuvation Bio NUVB Stock Holding History

Octagon Capital Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,633,334
Closed -$9.74M – 33
2025
Q3 		$9.74M Sell
2,633,334
-5,058,000
-66% -$13.8M 1.48% 20
2025
Q2 		$15M Sell
7,691,334
-208,666
-3% -$435K 3.29% 13
2025
Q1 		$13.9M Sell
7,900,000
-1,302,907
-14% -$2.97M 2.69% 13
2024
Q4 		$24.5M Sell
9,202,907
-2,968,606
-24% -$7.64M 4.03% 6
2024
Q3 		$27.9M Buy
12,171,513
+11,739,913
+2,720% +$35.8M 4.34% 8
2024
Q2 		$1.26M Sell
431,600
-943,270
-69% -$2.88M 0.2% 42
2024
Q1 		$5M Buy
1,374,870
+374,870
+37% +$720K 0.6% 37
2023
Q4 		$1.51M Buy
+1,000,000
New +$1.29M 0.24% 29

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Octagon Capital Advisors's NUVB Position: Q4 2025 in Review

Octagon Capital Advisors sold out of Nuvation Bio (NUVB) in Q4 2025, closing a stake of 2,633,334 shares — an estimated $9.74M sold.

Octagon Capital Advisors first reported a position in NUVB in Q4 2023 and held it in 8 quarters. The position peaked at $27.9M in Q3 2024. 223 funds tracked by Wall St. Rank hold NUVB as of Q4 2025.

  • Octagon Capital Advisors reported no remaining Nuvation Bio position as of Q4 2025 after selling out during the quarter.
  • Octagon Capital Advisors sold 2,633,334 Nuvation Bio shares in Q4 2025, an estimated $9.74M.
  • Octagon Capital Advisors first reported a position in Nuvation Bio in Q4 2023 and held it in 8 quarters.
  • Octagon Capital Advisors's Nuvation Bio position peaked at $27.9M in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2025.

Based on Octagon Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.